08 dec: Vestas-aktien ramt af Trump-udnævnelse af ny chef for EPA
08 dec: TDC vil købe obligationer tilbage for at reducere gæld - NY
08-12-2016 10:35:35

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
22 jun - 
Zealand/Jefferies: Fastholder købsanbefaling efter posi..
22 jun - 
Aktier/åbning: Overvejende sur stemning med fald til Mæ..
19 jun - 
Mandagens aktier: FLSmidth og Danske Bank førte an i fr..
Relateret debat
24 jun - 
Tak skal du have ES - det er jo nærmest en afhandling �..
24 jun - 
Hvor blev din sivekurs kommentar af?
24 jun - 
Hørt, om 10 år vil alle type-1 sandsynligvis blive beha..

Company announcement - No. 49 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 8 December 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 and the total proceeds to Zealand from the capital increase amounts to DKK 1,077,923.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,142,365 divided into 26,142,365 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe).  

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

49-16_1208 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 774036.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
24 jun
ZEAL
Tirsdag den 7. febuarar i år udsendte det amerikanske National Institute of Health  (NIH) en pressem..
20
22 jun
ZEAL
Glepaglutide - Fase II studiet kunne pege på at Glepagtide er bedre end Gattex. Det sekundær endpoin..
9
19 jun
ZEAL
Du kan bruge konkurrant produktet Gattex (teduglutide) som benchmark.Her varede studie 24 uger med l..
9
19 jun
ZEAL
I Februar 2015 opkøbte det irske pharma-selskab Shire det selskab som hed "NPS Pharmaceuticals" for ..
7
22 jun
ZEAL
Zealand Pharmas positive data fra fase 2-studier med glukagonanalogen Dasiglucagon til diabetesbehan..
5
18 jun
ZEAL
Det er nu ikke særlig pænt at dig at sige sådan om Goodwrench, Kenneth - de fleste ved vist udemærke..
5
21 jun
ZEAL
Du kan ikke drage noge konklusion ud fra det sidste tal men det er stort set det du gør. Du kan tale..
4
21 jun
ZEAL
4
20 jun
ZEAL
Så Jefferies vil lægge 20 kr på kursen og markedet vil lægge på 2 kr.    Det kræver så at nogen kan ..
4
18 jun
ZEAL
Læg mærke til det fine regnestykke Goodwrench har sat op til at underbygge hans kursmål på 80 kr.
4

Økonomisk planlægning

22-06-2017 09:52:24
Sponsoreret indhold:Alle har brug for en økonomisk plan. Men hvor skal du begynde? Vi forklarer hvordan i fire enkle trin.Selvom det kan virke overvældende at skulle planlægge sin økonomiske fremtid (der er så meget, der kan ske og så mange overvejelser), så behøver det ikke være stressende at lære at udarbejde en økonomisk plan, hvis du gør det rigtigt. Som alle store spørgsmål i livet er planlæg..

Aktier/tendens: Mærsk og Tryg kan komme i fokus

14-06-2017 08:08:45
A.P. Møller-Mærsk kan onsdag blive påvirket af kinesiske nøgletal og et løftet kursmål hos et større amerikansk finanshus, mens forsikringsselskabet Tryg kan blive presset af en sænket anbefaling af aktien af et italiensk finanshus.Overordnet set ventes det europæiske aktiemarked onsdag at åbne tæt på uændret, og mange investorer vil formentlig forholde sig afventende forud for resultatet af todag..

Carlsberg-konkurrent er klar til indrømmelser for britisk opkøb

13-06-2017 16:19:06
Den hollandske bryggerigigant Heineken, som blandt andet konkurrerer med Carlsberg, er parat til at komme med indrømmelser over for myndighederne i Storbritannien for at få lov til at overtage den britiske pubkæde Punch Taverns.Det skriver Bloomberg News, efter at de britiske konkurrencemyndigheder, Competition and Markets Authority (CMA), tidligere har advaret Heineken om, at selskabets overtagel..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 128,50 1,6% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. juni 2017 07:09:53
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170623.1 - EUROWEB1 - 2017-06-25 07:09:53 - 2017-06-25 07:09:53 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x